Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel
NASDAQ:PLUR

Pluri 5/13/2025 Earnings Report

Pluri logo
$3.30 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.32 +0.02 (+0.45%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pluri EPS Results

Actual EPS
-$0.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pluri Revenue Results

Actual Revenue
$0.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pluri Announcement Details

Quarter
Date
5/13/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pluri's next earnings date is estimated for Thursday, May 7, 2026, based on past reporting schedules.

Conference Call Resources

Pluri Earnings Headlines

Pluri (PLUR) Projected to Post Quarterly Earnings on Thursday
May 6 at 4:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30761420
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans
April 30, 2026  |  quiverquant.comQ
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 6 at 1:00 AM  |  American Alternative (Ad)
Pluri Announces Financing Through Unregistered Equity Securities Deal
March 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pluri-announces-financing-through-unregistered-equity-securities-deal?utm_source=marketbeat.com&utm_medium=referral
Pluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
March 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68049031-pluri-inc-pluri-secures-additional-investment-from-chairman-alejandro-weinstein-at-30-premium-to-market-in-a-private-placement-399.htm
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
March 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/pluri-secures-additional-investment-chairman-123000753.html
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases.

Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.

View Pluri Profile
Earnings Tools